Document is current
Any future updates will be listed below
-
Authors
Narui, Kazutaka
Ishikawa, Takashi
Takashima, Ikumi
Kashiwabara, Kosuke
Uemura, Yukari
Kikawa, Yuichiro
Taira, Naruto
Mukai, Hirofumi
- License Information
-
More Information
Article History
Received: 31 March 2024
Accepted: 1 May 2025
First Online: 7 May 2025
Declarations
:
: The previous FN study was approved by the protocol review committee of the Comprehensive Support Project for Oncological Research of Breast Cancer on February 10, 2015, and by the Institutional Review Board of Tokyo Medical University on April 28, 2015 (No. 3044). The study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained, and the privacy rights of the participants were observed.
: The authors declare the following financial interests/personal relationships that may be considered potential competing interests: KN has received honoraria from Eisai, Daiichi Sankyo, Pfizer, Lilly, Takeda, and Kyowa Kirin. His institution received research grants from Taiho, Eisai, Daiichi Sankyo, Chugai, and Takeda. TI has received honoraria from Daiichi Sankyo, Kirin, Pfizer, Chugai, Lilly, and AstraZeneca. YU received honoraria from Eisai, Lilly, Chugai, Pfizer, Daiichi Sankyo, and Novartis. YK received honoraria from Eisai, Lilly, Chugai, Pfizer, Daiichi Sankyo, and Novartis. NT received honoraria from AstraZeneca, Pfizer, Chugai, and Daiichi Sankyo. His institution received research grants from Taiho, Chugai, Kirin, Eisai, Daiichi Sankyo, Eli Lilly, and Takeda. HM also received honoraria from Takeda and Taiho. All the remaining authors have declared no conflict of interest associated with this study.
